Laying The Groundwork For Value-Based Healthcare In Europe
Elisabeth Aloy and David Pistor, healthcare and life sciences advisors at Monitor Deloitte, outline five design principles to create a value-based care project.
You may also be interested in...
The Outcomes-Based Reimbursement Experiment
US payers and drug companies are showing interest in outcomes-based contracts and even implementing some but whether they will become the reimbursement arrangements of the future remains highly uncertain.
Aetna: Entresto’s Label Enabled Outcome-Based Risk Share
Including the impact on hospitalizations in the label for Novartis's heart failure drug Entresto was critical to enable execution of outcome-based agreements. Such deals present an opportunity for pharma and payers to work together, but many challenges remain.
Novartis To Payers: Entresto Works Or You Get A Discount
Performance-based reimbursement agreements with US payers, like the deals that Novartis AG recently struck with Cigna Corp. and Aetna Inc. for the heart failure drug Entresto (sacubitril/valsartan), are rare, but Novartis US Head Christi Shaw said she's hopeful that the concept will catch on.